Wexford Capital LP Buys 15,000 Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM)

Wexford Capital LP boosted its position in Carisma Therapeutics, Inc. (NASDAQ:CARM) by 75.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,861 shares of the company’s stock after buying an additional 15,000 shares during the quarter. Wexford Capital LP owned approximately 0.08% of Carisma Therapeutics worth $34,000 at the end of the most recent reporting period.

Separately, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Carisma Therapeutics during the second quarter worth approximately $40,000. 44.27% of the stock is currently owned by institutional investors.

Carisma Therapeutics Trading Up 0.8 %

NASDAQ:CARM opened at $0.80 on Friday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics, Inc. has a 12 month low of $0.79 and a 12 month high of $3.16. The firm has a fifty day simple moving average of $0.94 and a two-hundred day simple moving average of $1.06. The stock has a market capitalization of $33.35 million, a price-to-earnings ratio of -0.51 and a beta of 1.44.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). The business had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Analysts expect that Carisma Therapeutics, Inc. will post -1.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CARM has been the subject of a number of recent research reports. EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. HC Wainwright lowered their price objective on shares of Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.